MONITORTAVI: Management of Patients With New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06148883
Collaborator
(none)
360
1
2
25
14.4

Study Details

Study Description

Brief Summary

The purpose of this study is to show that Electrocardiogram Ambulatory Monitoring-guided strategy is superior to ElectroPhysiological Study on the rate of alive patients with an appropriate Pacemaker implantation/non-implantation, at 12 months after randomization, in patients with New Onset Persistent Left Bundle Branch Block after Transcatheter Aortic Valve Implantation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Transcatheter Aortic Valve Implantation
N/A

Detailed Description

This is a prospective, multicentric, randomized in parallel group, controlled, open labelled clinical study.

  • After Transcatheter Aortic Valve Implantation, all consecutive patients presenting with new onset Left Bundle Branch Block will undergo in-hospital telemetry. In case of persistence (at least 48 hours) of a stable (i.e., no change in the last 24 hours) Left Bundle Branch Block > 150 ms, and in the absence of high grade Aortic Valve block or persistent prolonged PR interval > 240 ms, patients will be eligible for the study

  • After written consent will be obtained, included patients will be randomized into two groups according to a 1:1 ratio:

  • Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge. In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring. Any other clinically relevant therapeutic decision based on Electrocardiogram Ambulatory Monitoring will be taken or

  • ElectroPhysiological Study for infra-hisian conduction evaluation. Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms

  • Patients in both groups will be followed until the end of the first year after randomization. Follow-up visits will be scheduled in person at 1 and 12 months, and through telemedicine at 3 and 6 months. Appropriateness of Pacemaker implantation/non-implantation will be evaluated at each follow-up time

  • In case of any occurrence of syncope, patients will be evaluated in person, by the principal investigator of each centre, to evaluate and manage the syncope as recommended by the European Society of Cardiology guidelines.

Patients will be followed-up according to current practice.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
360 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomized in 2 parallel group studyThis is a randomized in 2 parallel group study
Masking:
None (Open Label)
Masking Description:
open labelled clinical study
Primary Purpose:
Treatment
Official Title:
Comparison of Early Ambulatory Monitoring Strategy Versus Electrophysiological Study Approach in the Management of Patients With New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge

In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring.

Procedure: Transcatheter Aortic Valve Implantation
Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously

Experimental: Electrocardiogram Ambulatory Monitoring for infra-hisian conduction evaluation

In this group, Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms.

Procedure: Transcatheter Aortic Valve Implantation
Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously

Outcome Measures

Primary Outcome Measures

  1. Alive status with appropriate Pacemaker implantation/non-implantation [12 months]

    The primary endpoint of this study is the alive status with appropriate Pacemaker implantation/non-implantation, at 12 months after randomization. Appropriate Pacemaker non-implantation: - Absence of syncope or sudden cardiac death in a non-implanted patient Appropriate Pacemaker implantation: Documented indisputable criteria for Pacemaker implantation Absence of syncope or sudden cardiac death Absence of upgrading procedure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Patients who are 18 years or older and undergo Transcatheter Aortic Valve Implantation :
  1. Presenting with New Onset Persistent Left Bundle Branch Block, defined as a new Left Bundle Branch Block >150 ms that persists at least two days after Transcatheter Aortic Valve Implantation and is stable

  2. With an anticipated life expectancy >1 year

  3. Who consent to participate to the study

Exclusion Criteria:
  1. During in-hospital Electrocardiogram monitoring period, immediately after
Transcatheter Aortic Valve Implantation and before inclusion:
  • Documented high grade Atrio Ventricular block (Atrio Ventricular block of a degree higher than Mobitz I)

  • Persistent PR interval prolongation > 240 ms

  • Occurrence of syncope or sudden cardiac death,

  • Identification of any indisputable criteria for Pacemaker implantation

  • Definitive Pacemaker implantation

  1. Prior Pacemaker or Implantable Cardiac defibrillator

  2. Indication for Cardiac Resynchronization Therapy or Implantable cardiac defibrillator

  3. Pre-existing Left Bundle Branch Block or Right Bundle Branch Block

  4. Pre-existing PR interval prolongation > 240 ms

  5. Severe or moderate dementia, evaluated before Transcatheter Aortic Valve Implantation, defined as a Mini Mental State Examination < 15

  6. Pregnancy or breastfeeding patient

  7. No affiliation to a social security scheme

  8. Adult under legal protection (trusteeship, guardianship).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital de la Timone - APHM Marseille France 13385

Sponsors and Collaborators

  • Assistance Publique Hopitaux De Marseille

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT06148883
Other Study ID Numbers:
  • 2022-A02699-34
First Posted:
Nov 28, 2023
Last Update Posted:
Nov 28, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 28, 2023